Johnson & Johnson Beats Q4 Estimates, Projects 2026 Free Cash Flow of $21B
Johnson & Johnson beat Q4 earnings and sales estimates and forecasts 2026 free cash flow rising to $21 billion. The company’s MedTech sales grew 5.4% to $33.8 billion and Innovative Medicine sales rose 5.3% to $60.4 billion, with 2026 revenues expected above $100 billion.
1. Q4 Earnings Beat and Ambitious Free Cash Flow Outlook
Johnson & Johnson reported fourth-quarter revenue of $24.6 billion, surpassing consensus estimates by roughly $500 million and marking 9.1% year-over-year growth. Adjusted earnings per share came in at $2.46, up from $2.04 a year earlier, driven by strong oncology and immunology sales and operational leverage. The company reaffirmed its view that 2026 free cash flow will reach $21 billion, up from approximately $19.7 billion in 2025, underpinned by robust operating performance and disciplined capital allocation.
2. Analyst Upgrades Signal Continued Momentum
Cowen & Co. maintained its Buy rating on the company and raised its 12-month price target from $222 to $250, citing accelerating sales in pharmaceuticals and medical devices. Zacks Investment Research’s Earnings ESP tool also identifies the company as well positioned to exceed upcoming earnings expectations. These bullish assessments follow confirmation of sustained revenue growth across core segments and strengthen the investment case for healthcare-focused exchange-traded funds as a means to capture the company’s momentum.
3. Dividend King Status and Fortress Balance Sheet
Johnson & Johnson extended its dividend for the 63rd consecutive year, supporting a current yield of approximately 2.4%. Last year’s free cash flow of $19.7 billion comfortably covered $12.4 billion in dividend payments, leaving ample headroom for continued increases. The balance sheet remains strong with $20 billion in cash and marketable securities against $48 billion in debt, preserving its AAA credit ratings and ensuring capacity for both shareholder returns and strategic investments.
4. MedTech and Innovative Medicine Driving Growth
The MedTech segment delivered $33.8 billion in operational sales in 2025, up 5.4% year over year, led by electrophysiology products and the integration of Shockwave Technology. Innovative Medicine achieved $60.4 billion in sales, growing 5.3%, fueled by Carvykti and key oncology franchise expansions. With 15 major product launches and more than 40 regulatory approvals last year, the company now counts 28 platforms generating over $1 billion each, positioning it to exceed $100 billion in total revenue for the first time in 2026.